GSA Capital Partners LLP Purchases Shares of 568,809 Editas Medicine, Inc. $EDIT

GSA Capital Partners LLP acquired a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 568,809 shares of the company’s stock, valued at approximately $1,166,000.

Other large investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new stake in Editas Medicine during the third quarter worth about $36,000. Captrust Financial Advisors bought a new stake in Editas Medicine during the second quarter worth about $26,000. Sei Investments Co. bought a new stake in Editas Medicine during the third quarter worth about $46,000. Baader Bank Aktiengesellschaft bought a new stake in Editas Medicine during the third quarter worth about $50,000. Finally, SG Americas Securities LLC bought a new stake in Editas Medicine during the third quarter worth about $51,000. 71.90% of the stock is owned by institutional investors.

Editas Medicine Price Performance

Shares of NASDAQ EDIT opened at $2.67 on Friday. The company’s 50 day simple moving average is $2.80 and its 200 day simple moving average is $2.42. Editas Medicine, Inc. has a fifty-two week low of $1.49 and a fifty-two week high of $4.54. The firm has a market capitalization of $261.42 million, a P/E ratio of -2.17 and a beta of 2.14.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Editas Medicine had a negative net margin of 281.59% and a negative return on equity of 677.39%. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $6.37 million. Sell-side analysts expect that Editas Medicine, Inc. will post -1.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on EDIT shares. Wall Street Zen cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Sunday, May 10th. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a research report on Monday, March 9th. JonesTrading upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, March 10th. Chardan Capital upped their target price on shares of Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Editas Medicine in a research report on Monday, April 20th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Editas Medicine presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.40.

Editas Medicine Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.